Abstract
Summary Patients with end-stage kidney disease (ESKD) are at high risk of severe COVID-19. We performed longitudinal single cell multi-omic immune profiling of ESKD patients with COVID- 19, sampled during two waves of the pandemic. Uniquely, for a subset of patients, we obtained samples before and during acute infection, allowing intra-individual comparison. Using single- cell transcriptome, surface proteome and immunoreceptor sequencing of 580,040 high-quality cells, derived from 187 longitudinal samples from 61 patients, we demonstrate widespread changes following infection. We identified gene expression signatures of severity, with the majority of pathways differentiating mild from severe disease in B cells and monocytes. For example, gene expression of PLAC8, a receptor known to modulate SARS-CoV-2 entry to cells, was a marker of severity in CD14+ monocytes. Longitudinal profiling demonstrated distinct temporal molecular trajectories in severe versus mild disease, including type 1 and type 2 interferon signalling, MHC gene expression and, in B cells, a proliferative signature (KRAS and MYC). Evaluation of clonal T cell dynamics showed that the fastest expanding clones were significantly enriched in known SARS-CoV-2 specific sequences and shared across multiple patients. Our analyses revealed novel TCR clones likely reactive to SARS- CoV-2. Finally, we identified a population of transcriptionally distinct monocytes that emerged in peripheral blood following glucocorticoid treatment. Overall, our data delineate the temporal dynamics of the immune response in COVID-19 in a high-risk population and provide a valuable open-access resource.
Competing Interest Statement
S.A.T is on the advisory board for Cell Genomics. L.M.D., R.G.H.L. and S.A.T. are inventors on a filed patent that is related to the detection and application of activated T cells. In the past three years, S.A.T. has received remuneration for Scientific Advisory Board Membership from Sanofi, GlaxoSmithKline, Foresite Labs and Qiagen. S.A.T. is a co-founder and holds equity in Transition Bio and Ensocell. From 8 January 2024, S.A.T is a part-time employee of GlaxoSmithKline. The other authors have no conflicts of interest.
Funding Statement
This work was funded by a UKRI-DHSC COVID-19 Rapid Response Rolling Call (MR/V027638/1) (to J.E.P.), funding from the UK Coronavirus Immunology Consortium (UK-CIC) and Wellcome Human Cell Atlas Strategic Science Support (WT211276/Z/18/Z), and the NIHR Imperial Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. M.H. is funded by Wellcome (221052/Z/20/Z, 215116/Z/18/Z), the Lister Institute for Preventive Medicine, and NIHR and Newcastle Biomedical Research Centre. L.M.D is supported by the European Union Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 955321. J.E.P. is supported by a fellowship from the Medical Research Foundation (MRF-057-0003-RG-PETE-C0799). M.C.P. is a Wellcome Trust Senior Fellow in Clinical Science (212252/Z/18/Z). C.L.C was supported by an Auchi Clinical Research Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants (patients and controls) were recruited from the Imperial College Healthcare NHS Trust Renal and Transplant Centre and its satellite dialysis units, London, United Kingdom, and provided written informed consent prior to participation. Study ethics were reviewed by the UK National Health Service (NHS) Health Research Authority (HRA) and Health and Care Research Wales (HCRW) Research Ethics Committee (reference 20/WA/0123: The impact of COVID-19 on patients with renal disease and immunosuppressed patients). Ethical approval was given.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data will be available online at https://covid19cellatlas.org/
